235 related articles for article (PubMed ID: 21599606)
1. Management of hairy cell leukemia variant.
Robak T
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():53-6. PubMed ID: 21599606
[TBL] [Abstract][Full Text] [Related]
2. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
3. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
Robak T
Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
[TBL] [Abstract][Full Text] [Related]
4. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
5. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
6. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment.
Robak T
Cancer Treat Rev; 2011 Feb; 37(1):3-10. PubMed ID: 20558005
[TBL] [Abstract][Full Text] [Related]
7. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
8. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
9. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
10. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
11. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
12. Immunobiological treatments of hairy-cell leukaemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2003 Mar; 16(1):117-33. PubMed ID: 12670470
[TBL] [Abstract][Full Text] [Related]
13. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
14. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
15. Approach to the patient after relapse of hairy cell leukemia.
Kreitman RJ; Fitzgerald DJ; Pastan I
Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
[TBL] [Abstract][Full Text] [Related]
16. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.
Quach H; Januszewicz H; Westerman D
Haematologica; 2005 Nov; 90 Suppl():ECR26. PubMed ID: 16266917
[TBL] [Abstract][Full Text] [Related]
17. Hairy cell leukemia: a 'hair-raising' update.
Topp ZZ; Saven A
Expert Rev Hematol; 2014 Oct; 7(5):659-69. PubMed ID: 25148599
[TBL] [Abstract][Full Text] [Related]
18. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
19. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.
Blasińska-Morawiec M; Robak T; Krykowski E; Hellmann A; Urbańska-Ryś H
Leuk Lymphoma; 1997 Apr; 25(3-4):381-5. PubMed ID: 9168448
[TBL] [Abstract][Full Text] [Related]
20. Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use.
Kang C
Clin Drug Investig; 2021 Sep; 41(9):829-834. PubMed ID: 34383256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
